MP26-01 PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB

Authors :: Syunsuke Yoshimine
Seiya Hattori
Koichiro Ogihara
Satoshi Hara
Takashi Okabe
Masafumi Oyama
Eiji Kikuchi
Suguru Shirotake
Ryuichi Mizuno
Takeshi Masuda
Masashi Niwakawa
Ryo Yamashita
Mototsugu Oya
Kazuhiro Matsumoto
Source :: Journal of Urology. 201
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.
Abstract: INTRODUCTION AND OBJECTIVES:No reliable biomarker is available for predicting worse clinical outcome in chemo-resistant urothelial carcinoma (UC) patients treated with pembrolizumab. We focused on ...

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Internal medicine
medicine
Biomarker (medicine)
Pembrolizumab
Neutrophil to lymphocyte ratio
business
Urothelial carcinoma

Tools